Predictors of posttraumatic stress following transient ischemic attack: An observational cohort study.
Ischemic attack, transient (TIA)
Mindfulness
Resilience, psychological
Sense of coherence
Social support
Stress disorder, post-traumatic (PTSD)
Journal
Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333
Informations de publication
Date de publication:
29 Jul 2020
29 Jul 2020
Historique:
received:
09
03
2020
revised:
15
06
2020
accepted:
26
07
2020
pubmed:
10
8
2020
medline:
10
8
2020
entrez:
10
8
2020
Statut:
aheadofprint
Résumé
Transient ischemic attack (TIA) has been reported to be frequently followed by symptoms of post-TIA posttraumatic stress disorder (post-TIA PTSD). Risk factors for post-TIA PTSD remain largely unknown. We aimed to identify predictors of post-TIA PTSD development to enable post-TIA PTSD risk assessment and inform future development of treatment and prevention interventions. TIA patients were examined twice for this observational cohort study. Symptoms of post-TIA PTSD, depression and anxiety were assessed shortly after TIA during in-hospital stay (T Sixty-one patients (83.6%) completed the study at T Post-TIA PTSD is a common phenomenon. General PTSD risk factors can be applied for post-TIA PTSD risk assessment. Sense of coherence and mindfulness are promising target variables for post-TIA PTSD treatment and prevention interventions.
Identifiants
pubmed: 32768689
pii: S0022-3999(20)30767-4
doi: 10.1016/j.jpsychores.2020.110205
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110205Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest TR received consulting honoraria, speakers' honoraria and travel support from BMS Pfizer, Boehringer Ingelheim, Bayer HealthCare and Daiichi Sankyo, outside the submitted work. PR received consulting honoraria, speakers' honoraria and travel support from Bayer Health Care, BMS, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer outside the submitted work. For the remaining authors none were declared.